BR112015023520A2 - purificação do conjugado de anticorpo-fármaco (adc) - Google Patents
purificação do conjugado de anticorpo-fármaco (adc)Info
- Publication number
- BR112015023520A2 BR112015023520A2 BR112015023520A BR112015023520A BR112015023520A2 BR 112015023520 A2 BR112015023520 A2 BR 112015023520A2 BR 112015023520 A BR112015023520 A BR 112015023520A BR 112015023520 A BR112015023520 A BR 112015023520A BR 112015023520 A2 BR112015023520 A2 BR 112015023520A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- drug
- adc
- purification
- adcs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
resumo purificação do conjugado de anticorpo-fármaco (adc) a invenção fornece métodos para obter composições que apresentam conjugados de anticorpo-fármaco (adcs) com razões de fármaco para anticorpo (dars) especificadas. incluído na invenção está um método para purificar uma mistura de adc que apresenta adcs com uma espécie carregada com fármaco de 6 ou mais através do contato da mistura com uma resina hidrofóbica, tal que uma composição compreendendo menos do que 15 % da espécie carregada com fármaco de 6 ou mais é obtida. a invenção também fornece uma composição em que 70 % ou mais do adcs presentes têm uma espécie carregada com fármaco de 4 ou menos, em que o adc compreende um anticorpo anti-egfr e uma auristatina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792834P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/027062 WO2014152199A1 (en) | 2013-03-15 | 2014-03-14 | Antibody drug conjugate (adc) purification |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015023520A2 true BR112015023520A2 (pt) | 2017-10-24 |
Family
ID=50686153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015023520A BR112015023520A2 (pt) | 2013-03-15 | 2014-03-14 | purificação do conjugado de anticorpo-fármaco (adc) |
Country Status (16)
Country | Link |
---|---|
US (2) | US20140286968A1 (pt) |
EP (2) | EP4137160A1 (pt) |
JP (1) | JP2016519070A (pt) |
KR (1) | KR20150132864A (pt) |
CN (1) | CN105209076A (pt) |
AU (1) | AU2014240012A1 (pt) |
BR (1) | BR112015023520A2 (pt) |
CA (1) | CA2906022A1 (pt) |
HK (2) | HK1217643A1 (pt) |
IL (1) | IL241004A0 (pt) |
MX (1) | MX2015012562A (pt) |
NZ (1) | NZ630888A (pt) |
RU (1) | RU2015144186A (pt) |
SG (2) | SG11201507432XA (pt) |
TW (1) | TW201519904A (pt) |
WO (1) | WO2014152199A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
SI2968588T1 (sl) * | 2013-03-15 | 2019-05-31 | AbbVie Deutschland GmbH & Co. KG | Formulacije konjugatov protitelo proti-EGFR zdravilo |
TW202214691A (zh) | 2014-03-21 | 2022-04-16 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
CN106999606B (zh) * | 2015-02-17 | 2020-06-19 | 上海美雅珂生物技术有限责任公司 | 抗体药物偶联物 |
WO2016144773A1 (en) | 2015-03-06 | 2016-09-15 | Abbvie Inc. | Arabinosylated glycoproteins |
EP3292149B1 (en) | 2015-05-04 | 2021-12-01 | CytomX Therapeutics, Inc. | Activatable anti-cd71 antibodies, and methods of use thereof |
AU2017277422A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
CA3027103A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
MX2018015280A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Conjugados de anticuerpo y farmaco anti-egfr. |
WO2017214335A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
CN109563167A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
KR102369014B1 (ko) * | 2016-08-16 | 2022-03-02 | 리제너론 파아마슈티컬스, 인크. | 혼합물로부터 개별 항체들을 정량하는 방법 |
TWI631958B (zh) * | 2016-11-02 | 2018-08-11 | 財團法人生物技術開發中心 | 抗tmcc3免疫共軛物及其用途 |
WO2018119351A1 (en) * | 2016-12-23 | 2018-06-28 | Bluefin Biomedicine, Inc. | Anti-sez6l2 antibodies and antibody drug conjugates |
CN107375941A (zh) * | 2017-07-17 | 2017-11-24 | 中国药科大学 | 一种抗人dll4单克隆抗体与海兔毒素衍生物mmae的偶联物 |
SG11202008770QA (en) | 2018-03-13 | 2020-10-29 | Zymeworks Inc | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
EP3980073A4 (en) * | 2019-06-07 | 2023-11-01 | Dyne Therapeutics, Inc. | PROCESSES FOR PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES |
CN114502593A (zh) | 2019-08-06 | 2022-05-13 | 葛兰素史密斯克莱知识产权发展有限公司 | 生物药物组合物和相关方法 |
CN112604004B (zh) * | 2019-09-19 | 2022-05-10 | 中国医学科学院医药生物技术研究所 | 一类抗人egfr抗体药物偶联物及其制备方法与应用 |
UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
KR20240040786A (ko) | 2021-08-03 | 2024-03-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
DE68921982T4 (de) | 1988-06-14 | 1996-04-25 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
CA2282504A1 (en) | 1997-02-25 | 1998-08-27 | Jun-Ping Xu | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
WO2002044209A2 (en) * | 2000-11-28 | 2002-06-06 | Zymogenetics, Inc. | Cytonkine receptor zcytor19 |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP1560599A1 (en) | 2002-11-14 | 2005-08-10 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
CA2559870A1 (en) * | 2004-04-07 | 2005-10-27 | Genetech,Inc. | Mass spectrometry of antibody conjugates |
AU2006269940C1 (en) | 2005-07-18 | 2013-11-07 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
WO2007018431A2 (en) | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
RU2011148913A (ru) * | 2009-05-01 | 2013-06-10 | Эбботт Лэборетриз | Иммуноглобулин с двумя вариабельными доменами и его применение |
US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
WO2013163631A2 (en) * | 2012-04-27 | 2013-10-31 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
-
2014
- 2014-03-14 JP JP2016502325A patent/JP2016519070A/ja active Pending
- 2014-03-14 SG SG11201507432XA patent/SG11201507432XA/en unknown
- 2014-03-14 EP EP22179414.2A patent/EP4137160A1/en not_active Withdrawn
- 2014-03-14 EP EP14722865.4A patent/EP2968589A1/en not_active Withdrawn
- 2014-03-14 BR BR112015023520A patent/BR112015023520A2/pt not_active IP Right Cessation
- 2014-03-14 KR KR1020157029906A patent/KR20150132864A/ko not_active Application Discontinuation
- 2014-03-14 NZ NZ630888A patent/NZ630888A/en not_active IP Right Cessation
- 2014-03-14 CA CA2906022A patent/CA2906022A1/en not_active Abandoned
- 2014-03-14 RU RU2015144186A patent/RU2015144186A/ru not_active Application Discontinuation
- 2014-03-14 AU AU2014240012A patent/AU2014240012A1/en not_active Abandoned
- 2014-03-14 TW TW103109819A patent/TW201519904A/zh unknown
- 2014-03-14 SG SG10201800313UA patent/SG10201800313UA/en unknown
- 2014-03-14 US US14/210,602 patent/US20140286968A1/en not_active Abandoned
- 2014-03-14 MX MX2015012562A patent/MX2015012562A/es unknown
- 2014-03-14 CN CN201480025357.3A patent/CN105209076A/zh active Pending
- 2014-03-14 WO PCT/US2014/027062 patent/WO2014152199A1/en active Application Filing
-
2015
- 2015-09-01 IL IL241004A patent/IL241004A0/en unknown
-
2016
- 2016-05-16 HK HK16105608.5A patent/HK1217643A1/zh unknown
- 2016-06-21 HK HK16107159.4A patent/HK1219056A1/zh unknown
-
2019
- 2019-02-11 US US16/273,034 patent/US20190262417A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1217643A1 (zh) | 2017-01-20 |
WO2014152199A1 (en) | 2014-09-25 |
SG11201507432XA (en) | 2015-10-29 |
HK1219056A1 (zh) | 2017-03-24 |
MX2015012562A (es) | 2016-06-21 |
RU2015144186A3 (pt) | 2018-03-19 |
US20140286968A1 (en) | 2014-09-25 |
KR20150132864A (ko) | 2015-11-26 |
SG10201800313UA (en) | 2018-02-27 |
JP2016519070A (ja) | 2016-06-30 |
TW201519904A (zh) | 2015-06-01 |
CN105209076A (zh) | 2015-12-30 |
CA2906022A1 (en) | 2014-09-25 |
NZ630888A (en) | 2017-06-30 |
US20190262417A1 (en) | 2019-08-29 |
EP4137160A1 (en) | 2023-02-22 |
EP2968589A1 (en) | 2016-01-20 |
IL241004A0 (en) | 2015-11-30 |
AU2014240012A1 (en) | 2015-09-24 |
RU2015144186A (ru) | 2017-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015023520A2 (pt) | purificação do conjugado de anticorpo-fármaco (adc) | |
BR112018011781A2 (pt) | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica | |
BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
BRPI0905733B8 (pt) | composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
BR112012010706A2 (pt) | composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
EA201791850A1 (ru) | Борсодержащие малые молекулы | |
BR112014017716A8 (pt) | composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol | |
EA201400311A1 (ru) | Аминозамещенные имидазопиридазины | |
BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
BR112015023209A8 (pt) | novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma | |
BR112016001446A8 (pt) | composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida | |
BRPI0810130A8 (pt) | Composição de bebida, processo para produzir uma composição de bebida, e, uso de uma composição de bebida | |
BR112018076639A2 (pt) | quimioterapias de combinação | |
MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
BR112015032200A2 (pt) | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo | |
PL423259A1 (pl) | Koniugaty przeciwciało-ureaza dla celów terapeutycznych | |
BR112013025696A2 (pt) | composição compreendendo cimento portland para utilização em vertebroplastia | |
BR112013000779A2 (pt) | composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial | |
MX2021011995A (es) | Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso. | |
BR112014018094A2 (pt) | composição de mistura contendo siloxanos amino-funcionais, partículas hidrofóbicas e silicones de elevado peso molecular e o seu uso para tratamento de couro | |
BR112012027393A2 (pt) | composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer | |
BR112014031306A2 (pt) | composição farmacêutica e respectivos usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61P 35/00 (2006.01) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 07/01/2020. |